Menzaghi Frederique Ph.D.'s Form 4 filing
Tvardi Therapeutics, Inc. (TVRD) · filed Mar 1, 2022
- Accession no.
- 0001209191-22-013986
- Filed
- Mar 1, 2022
- Trade date
- Feb 25, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $21.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Menzaghi Frederique Ph.D.CIK 0001597152 | Officer (Chief Scientific Off,SVP-R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2022 | Common Stock | AGrant or awardAcquired | +20,000 | $0.00 | $0 | 173,679 | Direct | |
| Feb 25, 2022 | Common Stock | SSaleDisposed | −2,114 | $10.29 | −$21,753.06 | 171,565 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2022 | Common Stock | AGrant or awardAcquired | +40,000 | $0.00 | $0 | 40,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.